Loading...
XSHG603456
Market cap1.74bUSD
Dec 25, Last price  
14.17CNY
1D
-0.28%
1Q
5.20%
Jan 2017
18.28%
IPO
108.69%
Name

Zhejiang Jiuzhou Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHG:603456 chart
P/E
12.26
P/S
2.29
EPS
1.16
Div Yield, %
2.83%
Shrs. gr., 5y
2.54%
Rev. gr., 5y
24.29%
Revenues
5.52b
+1.44%
590,669,767652,528,857833,378,939935,110,2281,143,419,7501,309,584,2041,286,206,7661,444,511,0851,653,177,2101,717,440,5991,862,225,1582,016,815,8532,647,284,1634,063,181,9155,445,105,1545,523,418,175
Net income
1.03b
+12.17%
41,423,75267,211,243109,859,779117,049,728136,256,784166,240,814133,278,522200,079,304111,480,460147,605,263157,147,456237,793,378380,584,950633,900,939921,170,3701,033,255,687
CFO
1.36b
+10.98%
82,841,684122,025,843105,299,432111,006,749154,281,690203,861,15310,167,664140,525,669136,646,433244,201,283264,782,500554,161,971400,392,398677,519,2361,225,782,0921,360,323,930
Dividend
Jul 04, 20240.5 CNY/sh
Earnings
Apr 07, 2025

Profile

Zhejiang Jiuzhou Pharmaceutical Co., Ltd manufactures and sells active pharmaceutical ingredients (API) and intermediates in China and internationally. Its API pipeline comprise central nervous system, non-steroidal, anti-infection, hypoglycemic and antiviral, tumor treatment, anti-depressant, Parkinson, HCV drugs, diabetes, cardiovascular, and respiratory anti-infection drugs. The company also provides asymmetric catalysts and lithium battery materials. Zhejiang Jiuzhou Pharmaceutical Co., Ltd was founded in 1973 and is headquartered in Taizhou, China.
URL
http://www.jiuzhoupharma.com
IPO date
Oct 10, 2014
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
5,523,418
1.44%
5,445,105
34.01%
4,063,182
53.48%
Cost of revenue
4,017,233
3,999,154
3,011,586
Unusual Expense (Income)
NOPBT
1,506,185
1,445,952
1,051,596
NOPBT Margin
27.27%
26.56%
25.88%
Operating Taxes
149,270
183,272
110,589
Tax Rate
9.91%
12.67%
10.52%
NOPAT
1,356,915
1,262,680
941,008
Net income
1,033,256
12.17%
921,170
45.32%
633,901
66.56%
Dividends
(358,649)
(208,575)
(166,277)
Dividend yield
1.66%
0.59%
0.35%
Proceeds from repurchase of equity
(65,287)
BB yield
0.30%
Debt
Debt current
7,768
256,854
499,845
Long-term debt
412,839
105,187
207,976
Deferred revenue
109,116
101,196
97,309
Other long-term liabilities
50,767
25,757
2
Net debt
(2,907,698)
(848,509)
(514,051)
Cash flow
Cash from operating activities
1,360,324
1,225,782
677,519
CAPEX
(929,442)
Cash from investing activities
(1,056,803)
Cash from financing activities
2,102,185
582,429
FCF
174,268
862,927
685,547
Balance
Cash
3,206,427
1,095,426
1,146,865
Long term investments
121,877
115,124
75,007
Excess cash
3,052,133
938,295
1,018,713
Stockholders' equity
3,864,621
3,407,502
2,651,522
Invested Capital
6,049,532
4,806,061
4,255,448
ROIC
25.00%
27.87%
23.30%
ROCE
16.37%
24.71%
19.65%
EV
Common stock shares outstanding
890,738
829,660
834,080
Price
24.21
-42.94%
42.43
-24.58%
56.26
57.15%
Market cap
21,564,759
-38.74%
35,202,459
-24.98%
46,925,351
63.17%
EV
18,728,999
34,428,871
46,411,300
EBITDA
1,888,004
1,794,149
1,343,673
EV/EBITDA
9.92
19.19
34.54
Interest
25,208
22,376
24,866
Interest/NOPBT
1.67%
1.55%
2.36%